Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
Address: 101 rue de Tolbiac 75654 Paris Cedex 13 ,France
Tel: +33 (0)1 44 23 60 98
Created in 1964, the National Institute of Health and Medical Research is a public scientific and technological, under the joint supervision of the Ministry of Health and Ministry of Research.
Inserm is the only public research body entirely dedicated to French human health. In 2008 Inserm was givin the responsibility for coordinating strategic, scientific and operational biomedical research. This central role of coordinator is a natural fit due to the scientific quality of our teams, as well as our ability to deliver translational research from bench to bedside.
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
